I think this is the rest of it....again, pretty rough, but maybe you'll get an idea of what's up.
Champions of the relationship with Israel and Zionism derives in part of Sidrnsky, who currently resides in Israel as part of a sabbatical at the Weizmann Institute. Champions already has marketing operations in Israel and employs a number of employees at the branch in Ra'anana for marketing the services of her VIP patients. Like - yes, Champions signed two contracts with Teva. One, signed directly with the nature of its support in developing cancer drugs, and other potential scale of $ 27 million, was signed in front of a dish cancer drug company, Teva acquired just before it. Malhi said in an interview with Globes, that another reason for the activity in Israel is a potential support of the Chief Scientist. "The company may take advantage of the scientist development grants. Like - yes, Israel is interesting to raise capital for government support for local venture capital funds, both biomedical and general. Incubator program also interesting. We also cross-eyed toward the involvement of greenhouse - not as a project incubator but perhaps biotech incubator's franchise. But this move is currently only an initial examination ", said salts.
Furthermore, he recently invested $ 9.4 million in the company led by Battery Ventures. This support is intended to increase the activity of personality tests, pharmaceutical companies and service the VIP services. Drug development is a lengthy process more expensive and not necessarily suitable for new investors, so we set up the company - Beth.
Most companies operating in the model of service in recent years actually added elements of drug development, to make them dream. Are you going in the opposite direction.
Salts: 'Yes, but the service model and ensures stable Champions to investors, and the company will enjoy the rise in value because it has shares in the company - the daughter. I believe the greatest value lies in developing remedies.
Custom Mouse
To understand the technology of the spin - off the new, one must understand the background of Champions. The VIP service its goes like this: The company takes a sample from a patient's own tumor and planting it in dozens of mice. That, in fact, it catches them cancer. Each mouse receives a different protocol of medication, to see what is drug combination is expected to be very effective in treating the specific tumor of one patient. This major upgrade of the existing treatment of cancer, where trial and error process is the patient himself.
Future intention is to make treatment accessible to every budget. That is, use the classification of cancer in mice many different types to find out what treatment suits all of them, and then - then develop tests compiling all the growth in a human patient according to type. Champions signed contracts with nature and a dish with many other companies, based also on mice with human tumors. "We offer companies test their product on our mice collection. It's much better tried to live all of which it increased and much closer to experiment on human cancer patients.
In addition to that she had, the company has located at the University of British Columbia is a cure for cancer that develops independently, go in the first phase of clinical trials in the fourth quarter. This product flowing - Oh. "We told ourselves that if our platform knows to scan cancer therapeutics and indicate those that have a chance of success, why not do such scanning to select drugs and developed upon ourselves," says Malhi. The drug, Irinofor, based on the technology of wrapping an existing drug - Irinotecan - a layer of fat molecules. Champions studied the effectiveness of the drug on its animal model and saw that it is efficient and that side effects are few. If the drug succeeds, will it also confirmed the model of Champions itself.
